Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034Martin J. van den Bent, Thierry Gorlia, R. Rampling et al.|Journal of Clinical Oncology|2009Cited by 573